51522-07-7

Usage

InChI:InChI=1/C8H7ClO4S/c1-14(12,13)7-4-5(8(10)11)2-3-6(7)9/h2-4H,1H3,(H,10,11)/p-1

Upstream product

• 2494-79-3 4-chloro-3-(chlorosulfonyl)benzoic acid 
• 79-08-3 bromoacetic acid 
• 157069-50-6 4-chloro-3-(methylsulfonyl)benzoic acid methyl ester 
• 74-11-3 para-chlorobenzoic acid 
• 200423-20-7 4-Chloro-3-hydroxysulfinylbenzoic acid 
• 74-88-4 methyl iodide 
• 79-11-8 chloroacetic acid 

Downstream Products

• 190367-99-8 4-(3-Hydroxy-piperidin-1-yl)-3-methanesulfonyl-benzoic acid 
• 135051-09-1 3-methylsulfonyl-4-(1-piperidino)benzoic acid 
• 34263-58-6 4-Amino-3-methylsulfonylbenzoesaeure 
• 404964-28-9 methyl 4-amino-3-methanesulfonylbenzoate 
• 404963-75-3 methyl 4-(5-chloro-3-methylbenzo[b]thiophene-2-sulfonylamino)-3-methanesulfonylbenzoate 
• 404963-90-2 TY-51076 
• 149725-39-3 N-(3-Methanesulfonyl-4-piperidin-1-yl-benzoyl)-guanidine 
• 200423-21-8 3-methylsulfonyl-4-(1-piperidino)benzoyl chloride 
• 149725-40-6 N-(3-Methanesulfonyl-4-piperidin-1-yl-benzoyl)-guanidine; compound with methanesulfonic acid 
• 175154-44-6 N-diaminomethylene-3-methylsulfonyl-4-(2-pyrazinyloxy)benzamide 
• 1186514-83-9 N-(1-(4-chloro-3-(methylsulfonyl)phenyl)ethyl)-4'-methyl-5-(pyrrolidine-1-carbonyl)biphenyl-3-carboxamide 
• 1186518-70-6 4-(1-azodoethyl)-1-chloro-2-(methylsulfonyl)benzene 
• 1186519-64-1 1-(4-chloro-3-(methylsulfonyl)phenyl)ethanol 
• 1186519-63-0 1-(4-chloro-3-(methylsulfonyl)phenyl)ethanone 

Relevant academic research and scientific papers

2,3,5 TRISUBSTITUTED ARYL AND HETEROARYL AMINO DERIVATIVES, COMPOSITIONS, AND METHODS OF USE

Compounds are disclosed that have a formula represented by the following:(I) wherein Cy, L1 R1, R2a, R2b, R3, R4, n, and L2 are as described herein. These compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example addictive disorders, Alzheimer's Disease, anxiety disorders, ascites, autism, bipolar disorder, cancer, depression, endothelial corneal dystrophy, edema, epilepsy, glaucoma, Huntington's Disease, inflammatory pain, insomnia, ischemia, migraine, migraine with aura, migraine without aura, neuropathic pain, nociceptive neuralgia, nociceptive pain, ocular diseases, pain, itch, excessive itch, Pruritis, neuropathic pruritis, Parkinson's disease, personality disorders, postherpetic neuralgia, psychosis, schizophrenia, seizure disorders, tinnitus, and withdrawal syndromes.

AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF

Compounds are provided according to formula (1 ) : where A, B, W, X', L, R1, R3, R4b, and m' are as defined herein. Provided compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, cognitive disorders, anxiety, depression, and others.

Structure-activity relationship of benzo[b]thiophene-2-sulfonamide derivatives as novel human chymase inhibitors

We have identified a new class of chymase inhibitor through a substituent analysis of MWP00965, which we previously discovered by in silico screening. TY-51076 (7) showed high potency (IC50=56 nM) and excellent selectivity for chymase compared to chymotrypsin and cathepsin G (>400-fold). The synthesis and structure-activity relationship of this class are described.

Synthesis of the highly selective Na+/H+ exchange inhibitors cariporide mesilate and (3-methanesulfonyl-4-piperidino-benzoyl) guanidine methanesulfonate

The syntheses of cariporide mesilate ((4-isopropyl-3-methanesulfonyl-benzoyl) guanidine methanesulfonate, HOE 642, CAS 159138-81-5), currently being clinically investigated as a protective drug in cardiac ischemia and reperfusion states, and of HOE 694 ((3-methanesulfonyl-4-piperidino-benzoyl)guanidine methanesulfonate, CAS 149725-40-6), widely used as a physiological and pharmacological research tool in studies comprising Na+/H+ exchange (NHE) inhibition, are described. Additionally, their selectivity on the different subtypes is disclosed.

Benzoylguanidines, a process for their preparation, their use as medicaments and medicaments containing them

Benzoylguanidines of the formula I STR1 where R(1) or R(2) is equal to R(6)--S(O)n -- or R(7)R(8)N--O2 S-- and the other substituent R(1) or R(2) is in each case equal to H, F, Cl, Br, I, alkyl, alkoxy or phenoxy, R(6)--S(O)n or R(7)R(8)N-- and R(6) is equal to alkyl, cycloalkyl, cyclopentylmethyl, cyclohexylmethyl or phenyl, R(7) and R(8) are equal to alkyl or phenylakyl or phenyl, and in which R(7) and R(8) may also together be a C4 -C7 chain, and in which R(7) and R(8), together with the nitrogen atom to which they are bonded, may be dihydroindole, tetrahydroquinoline or tetrahydroisoquinoline system, and where R(3), R(4) and R(5) are equal to hydrogen or alkyl, or R(3) and R(4) are together an alkylene chain or R(4) and R(5) are together an alkylene chain, and where n is equal to zero, 1 or 2 and their pharmaceutically tolerable salts are outstanding antiarrhythmics.

3-Amino-5-sulfonylbenzoic acids

Aminobenzoic acids of the structure SPC1 Having saluretic and diuretic properties are described. These compounds are prepared by amidation of a 2-halo analog thereof or by alkylation of the free amino compound.